Phosphocholine-Decorated PPI-Dendrimers Mimic Cell Membrane Phosphocholine Clusters and Tune the Innate Immune Activity of C-Reactive Protein.

C-reactive protein (CRP) is widely used as biomarkers of infection and inflammation. It has a well-described ability to bind phosphocholine (PC), as well as PC-clusters from compromised and inflamed cell membranes and tissues. The binding of PC-clusters to CRP is of interest as this binding determines subsequent innate immune activity. We investigated PC-decorated dendrimers as mimics for PC-clusters. Five generations of poly(propylene imine) (PPI) dendrimers were modified with PC surface groups via a three-step synthetic sequence obtaining the PC-decorated dendrimers in high purity. The dendrimers were analyzed by NMR and infrared spectroscopy as well as HPLC. We developed immunoassays to show that dendrimer-PC binding to CRP was Ca2+-dependent with an apparent overall Kd of 11.9 nM for first generation (G1) PPI-PC, while G2-PPI-PC and G3-PPI-PC had slightly higher affinities, and G4-PPI-PC and G5-PPI-PC had slightly lower affinities. For all PC-dendrimers, the affinity was orders of magnitude higher than the affinity of free phosphocholine (PC), indicating a PC-cluster effect. Next, we investigated the binding of CRP:PPI-PC complexes to complement component C1q. C1q binding to CRP was dependent on the generation of PPI-PC bound to CRP, with second and third generation PPI-PCs leading to the highest affinity. The dendrimer-based approach to PC-cluster mimics and the simple binding assays presented here hold promise as tools to screen PC-compounds for their abilities to tune the innate immune activity of CRP.

The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy.

KBP-088 (KeyBiosciencePeptide 088) is a potent dual amylin and calcitonin receptor agonist (DACRA). DACRAs are known to elicit potent activity in terms of typical amylin-induced responses, such as reducing food intake and body weight. However, to what extent amylin infusion can mimic the effects of the dual agonist KBP-088 is unknown. We studied the effect of acute dosing with KBP-088 (5 µg/kg) and rat amylin (100, 300, and 1000 µg/kg) and subsequently compared the chronic effect of KBP-088 (5 µg/kg per day) to increasing doses of rat amylin (100, 300, and 1000 µg/kg per day) delivered by continuous subcutaneous infusion, in high-fat diet (HFD) fed Long-Evans rats. Furthermore, acute amylin sensitivity was investigated. Single dose KBP-088 (5 µg/kg) potently reduced acute food intake for a prolonged period compared with amylin (100, 300, and 1000 µg/kg), confirming the difference in potency. Independent of dose, chronic amylin administration (100, 300, and 1000 µg/kg per day) was less effective than KBP-088 (5 µg/kg per day) in inducing body weight loss (15% with KBP-088, and 5%, 9%, and 8% with amylin, vehicle corrected) and reducing overall adiposity in HFD rats. Moreover, KBP-088 improved oral glucose tolerance with significantly reduced insulin levels (80% reduction) that were better than all doses of amylin (68%, 53%, and 7% reduction). Acute amylin sensitivity was independent of the chronic treatment. Dual activation of amylin and calcitonin receptors by KBP-088 is superior to amylin in reducing body weight and improving glucose tolerance, indicating a role for the calcitonin receptor.